Grace Therapeutics, Inc. Cash Flow Conversion Efficiency
Grace Therapeutics, Inc. cash flow conversion efficiency. Based on the latest financial reports, Grace Therapeutics, Inc. (GRCE) has a cash flow conversion efficiency ratio of -0.034x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.22 Million) by net assets ($64.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Grace Therapeutics, Inc. (2010–2025)
Cash flow conversion efficiency of Grace Therapeutics, Inc. from 2010 to 2025. This chart illustrates how Grace Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Grace Therapeutics, Inc. stock price today for real-time trading data and today's change.
Grace Therapeutics, Inc. Cash Flow Conversion Ratio Explained
Grace Therapeutics, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Grace Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Grace Therapeutics, Inc. ranked by their cash flow conversion efficiency. Also see market cap of Grace Therapeutics, Inc. for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Inhome Prime Properties SOCIMI S.A.
MC:YIPP
|
-0.032x |
|
Ledtech Electronics Corp
TW:6164
|
0.027x |
|
Aurora Mobile Ltd
NASDAQ:JG
|
0.048x |
|
Morixe Hermanos SACI
BA:MORI
|
0.000x |
|
Atlas Engineered Products Ltd
V:AEP
|
0.050x |
|
Brixton Metals Corporation
V:BBB
|
-0.147x |
|
Focus Graphite Inc
V:FMS
|
0.055x |
|
Riverstone Credit Opportunities Income Plc
LSE:RCOI
|
0.060x |
Annual Cash Flow Conversion Efficiency for Grace Therapeutics, Inc. (2010–2025)
The table below shows the annual cash flow conversion efficiency of Grace Therapeutics, Inc. from 2010 to 2025. Review how much free cash does Grace Therapeutics, Inc. generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $66.61 Million | $-14.90 Million | -0.224x | -12.02% |
| 2024-03-31 | $61.74 Million | $-12.33 Million | -0.200x | +14.70% |
| 2023-03-31 | $67.95 Million | $-15.91 Million | -0.234x | -47.11% |
| 2022-03-31 | $108.27 Million | $-17.23 Million | -0.159x | +38.13% |
| 2021-03-31 | $55.66 Million | $-14.32 Million | -0.257x | +85.43% |
| 2020-03-31 | $12.99 Million | $-22.95 Million | -1.766x | +21.30% |
| 2019-03-31 | $11.04 Million | $-24.79 Million | -2.244x | -47.43% |
| 2018-03-31 | $6.37 Million | $-9.69 Million | -1.522x | -530.30% |
| 2016-03-31 | $20.09 Million | $-4.85 Million | -0.242x | -11.49% |
| 2015-03-31 | $26.56 Million | $-5.75 Million | -0.217x | -5.95% |
| 2014-03-31 | $29.91 Million | $-6.12 Million | -0.204x | +22.00% |
| 2013-03-31 | $9.50 Million | $-2.49 Million | -0.262x | +32.45% |
| 2012-03-31 | $14.55 Million | $-5.65 Million | -0.388x | -18.23% |
| 2011-03-31 | $5.83 Million | $-1.91 Million | -0.328x | +30.67% |
| 2010-03-31 | $4.02 Million | $-1.90 Million | -0.473x | -- |
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a top… Read more